A61K 31/712
Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or
Official title: Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
A61K31/712 (Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or) appears on 413 US grants and 936 published applications in this corpus.
Search patents in A61K- Granted patents
- 413
- Published applications
- 936
- Assignees
- 424
- Inventors
- 1,729
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 2 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 3 | 0 |
| 2002 | 2 | 3 |
| 2003 | 1 | 4 |
| 2004 | 2 | 3 |
| 2005 | 0 | 3 |
| 2006 | 1 | 8 |
| 2007 | 1 | 3 |
| 2008 | 0 | 4 |
| 2009 | 0 | 19 |
| 2010 | 5 | 15 |
| 2011 | 13 | 15 |
| 2012 | 6 | 22 |
| 2013 | 6 | 21 |
| 2014 | 16 | 21 |
| 2015 | 19 | 33 |
| 2016 | 24 | 39 |
| 2017 | 30 | 41 |
| 2018 | 19 | 57 |
| 2019 | 31 | 51 |
| 2020 | 29 | 61 |
| 2021 | 38 | 66 |
| 2022 | 41 | 87 |
| 2023 | 32 | 74 |
| 2024 | 43 | 68 |
| 2025 | 24 | 94 |
| 2026 | 22 | 124 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Double-stranded RNAi agents for targeting and regulating HBV gene expression, and a use thereof6 Oct 2026US 12,753,409 B2Hangzhou Tianlong Pharmaceutical Co., Ltd.
- Antagonism as a therapy for TDP-43 proteinopathies25 Aug 2026US 12,716,065 B2University of Southern California
- Compositions and methods for inhibiting XDH expression18 Aug 2026US 12,709,752 B2Novo Nordisk A/S
- Cellular delivery methods4 Aug 2026US 12,698,307 B2PYC Therapeutics Limited
- Inhibitors of micro-RNA 2228 Jul 2026US 12,691,135 B2Aalborg University
- Methods of treatment of chronic kidney disease8 Oct 2026US 2026/0308590 A1AstraZeneca AB
- Compositions and methods for regulating expression of atxn28 Oct 2026US 2026/0308591 A1Riboway Therapeutics, Inc.
- Short interfering nucleic acid (sina) molecules targeting angptl 3 and angptl 8 and methods of using the same1 Oct 2026US 2026/0297581 A1Aligos Therapeutics, Inc.
- Alk7 rna interference agents1 Oct 2026US 2026/0297588 A1Eli Lilly and Company
- Pde3b rna interference agents1 Oct 2026US 2026/0297590 A1Eli Lilly and Company
Most cited
By later US patents
- Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof518US 5,550,111 ATemple University of the Commonwealth System of Higher Education · 1996
- Lipid formulation340US 8,158,601 B2Alnylam Pharmaceuticals, Inc. · 2012
- Lipid formulation126US 8,802,644 B2Tekmira Pharmaceuticals Corporation · 2014
- Non-liposomal systems for nucleic acid delivery117US 9,404,127 B2Protiva Biotherapeutics, Inc. · 2016
- Lipid formulations115US 9,394,234 B2Arbutus Biopharma Corporation · 2016